Anesthesia for a Patient with Mitral Stenosis Posted for Laparoscopic Appendicectomy

1. Introduction / Importance

2. Pathophysiology Relevant to Anesthetic Management

• The normal mitral valve area (MVA) is 4-6 cm²; symptoms begin when MVA falls below 1.5 cm²
• Narrowed orifice creates a fixed transvalvular gradient dependent on heart rate, cardiac output, and rhythm
• Tachycardia reduces diastolic filling time - dramatically worsening the gradient (ΔP = 4v² by modified Bernoulli) and raising left atrial pressure (LAP)
• Elevated LAP → pulmonary venous hypertension → pulmonary edema
• Chronic elevation → irreversible pulmonary vascular resistance (PVR) increase → right ventricular (RV) failure
• Loss of atrial kick in atrial fibrillation (AF) normally costs 20-30% of ventricular filling
• LV is chronically underloaded - low LVEDP, low LVEDV; LV function is often preserved
• Common associations: AF, left atrial thrombus, systemic emboli, tricuspid regurgitation

3. Preoperative Assessment and Optimization

3a. Clinical History and Examination

• Severity of MS: MVA, mean gradient, symptoms (NYHA class), exercise tolerance
• Presence of AF and ventricular rate control
• Anticoagulation status (warfarin / LMWH) - check INR
• History of emboli, pulmonary hypertension, infective endocarditis
• Current medications: digoxin, beta-blockers, diuretics, ACE inhibitors, anticoagulants

3b. Investigations

3c. Preoperative Optimization

• Optimize cardiac medications: maintain beta-blocker for rate control (target HR 60-80 bpm)
• Diuretics to achieve euvolemia - neither overloaded nor hypovolemic
• Anticoagulation bridging: if on warfarin for AF/thrombus, bridge with LMWH; stop warfarin 5 days before surgery; restart postoperatively
• Treat AF aggressively: rate control is mandatory; rhythm control if feasible
• Correct anemia (Hb should be > 10 g/dL to ensure adequate oxygen delivery at reduced CO)
• Antibiotic prophylaxis for IE: NOT routinely recommended for laparoscopic GI procedures unless high-risk valve features are present (prosthetic valve, previous IE)
• Risk stratification using Lee's Revised Cardiac Risk Index (RCRI)

4. Hemodynamic Goals (The "MS Goals" - Core of the Answer)

5. Specific Concerns with Laparoscopic Surgery

• 30% decrease in cardiac output initially (reduced venous return)
• ↑ SVR and ↑ MAP - increased LV afterload
• ↑ PVR - worsens pulmonary hypertension in MS patients
• CO2 absorption → hypercarbia → respiratory acidosis - worsens PVR
• ↑ Intra-abdominal pressure compresses IVC - reduces venous return
• Trendelenburg position increases venous return suddenly - may precipitate pulmonary edema in MS
• Catecholamine release (neurohumoral) → tachycardia risk

• Limit insufflation pressure to ≤12 mmHg (not the standard 14-15 mmHg)
• Maintain normocapnia with controlled ventilation - use capnography and ABG to detect CO2 absorption
• Consider gasless laparoscopy or open appendicectomy if MS is severe
• Avoid steep Trendelenburg; use gradual position changes
• Liberal ventilation settings (minute ventilation ↑) to compensate for CO2 absorption

6. Monitoring

• Invasive arterial line (IBP): Recommended - beat-to-beat BP, easy ABG sampling
• Central venous catheter (CVP): Guides fluid management; watch for prominent CV waves (tricuspid regurgitation)
• Transesophageal Echocardiography (TEE): Gold standard intraoperative monitor for volume status, wall motion, pulmonary artery pressures, RV function
• Pulmonary Artery Catheter: For severe MS with pulmonary hypertension - note: PCWP reflects transvalvular gradient, not LVEDP; use with caution given PA rupture risk in severe PHT
• Temperature monitoring: Hypothermia causes peripheral vasoconstriction and tachycardia

7. Choice of Anesthetic Technique

7a. General Anesthesia vs. Regional

• Laparoscopic appendicectomy requires general anesthesia with endotracheal intubation - essential for airway control, controlled ventilation, and management of CO2 pneumoperitoneum
• Spinal/epidural anesthesia: relative contraindication in severe MS due to rapid sympathetic blockade causing vasodilation (↓ SVR, ↓ preload) and reflex tachycardia

7b. Induction

• Technique: Slow, controlled induction to avoid tachycardia and hypotension
• Agents:
  • Fentanyl/remifentanil: Given before laryngoscopy to blunt sympathetic response (prevents tachycardia)
  • Etomidate: Preferred induction agent - hemodynamically stable, minimal effect on SVR/CO
  • Propofol: Use with caution - causes vasodilation and hypotension; if used, give slowly at low dose
  • Thiopentone: Avoid - significant myocardial depression and hypotension
  • Ketamine: Avoid - causes tachycardia via sympathetic stimulation
• Muscle relaxant: Vecuronium or rocuronium - hemodynamically neutral; avoid succinylcholine if tachycardia is a concern (minimal issue but vecuronium preferred)
• Preoxygenation is essential

7c. Maintenance

• Volatile agents: Isoflurane, sevoflurane, or desflurane - isoflurane/sevoflurane preferred; desflurane at high concentrations causes sympathetic activation (tachycardia risk)
• Opioids: Fentanyl, morphine; avoid meperidine (pethidine) - causes tachycardia
• Nitrous oxide: Avoid - increases PVR in patients with pulmonary hypertension
• Ventilation: Controlled mechanical ventilation with mild hyperventilation to counteract CO2 absorption from pneumoperitoneum; PEEP use cautiously (can raise PVR)

7d. Intraoperative Hemodynamic Management

• Tachycardia: Deepen anesthesia with opioids; IV esmolol (25-50 mg) or metoprolol (2.5-5 mg); amiodarone if AF with fast ventricular rate
• Hypotension: Phenylephrine (pure alpha-agonist, preferred) - raises SVR without tachycardia; vasopressin or norepinephrine are alternatives; avoid ephedrine - beta-adrenergic activity causes tachycardia
• SVT/AF with hemodynamic instability: DC cardioversion
• Fluid management: Judicious - avoid both deficit and overload; use 500-1000 mL crystalloid preload cautiously; guided by TEE/CVP
• Pulmonary edema: IV furosemide, PEEP, oxygen, reduce fluid

8. Postoperative Care

• Recovery in HDU/ICU if moderate-severe MS - close monitoring for 24-48 hours
• Continue heart rate control medications (restart oral beta-blockers early)
• Adequate analgesia - pain causes tachycardia; multimodal analgesia (paracetamol + NSAIDs [cautiously] + local wound infiltration); minimize opioid side effects
• Anticoagulation: Resume as soon as surgical bleeding risk allows
• Monitor for: pulmonary edema, RV failure, atrial fibrillation, systemic emboli, hypoxemia
• Supplemental oxygen in recovery
• Optimize fluid balance with diuretics as needed post-op
• Watch for aspiration risk - delayed gastric emptying in laparoscopic surgery

9. Contraindications to Proceed / When to Escalate

• Very severe MS (MVA < 1.0 cm²) with symptoms: Consider preoperative percutaneous balloon mitral valvotomy (PBMV) before elective/semi-elective surgery
• Severe pulmonary hypertension (PAP > 60 mmHg): Extremely high-risk; consider conversion to open approach
• Decompensated RV failure or pulmonary edema: Postpone, optimize first
• Uncontrolled AF with rapid ventricular rate: Control before proceeding

10. Summary Table

• Morgan & Mikhail's Clinical Anesthesiology, 7e, pp. 758-761 (Mitral Stenosis: Preoperative & Anesthetic Management)
• Miller's Anesthesia, 10e, pp. 7619-7622 (Anesthetic Management of Mitral Stenosis)
• Barash's Clinical Anesthesia, 9e, p. 4291 (Physiology of Pneumoperitoneum)
• Fuster & Hurst's The Heart, 15e (Perioperative Valvular Heart Disease)

1. Pathophysiology and why MS is high-risk - fixed output, tachycardia intolerance
2. Hemodynamic goals ("slow, full, tight, maintain" - HR slow, preload full, SVR tight/normal, rhythm maintained)
3. Specific laparoscopy risks: pneumoperitoneum ↓CO, ↑SVR, ↑PVR, hypercarbia
4. Monitoring with IBP, CVP, TEE
5. Drug choices: etomidate induction, phenylephrine for hypotension, esmolol for tachycardia, avoid ketamine/ephedrine/N2O
6. Postoperative HDU care